SCHEMBL2747590

SCHEMBL2747590

CNC(=O)c1cc(Oc2ccc3c(NC(=O)Nc4ccc(Cl)cc4)cccc3c2)ccn1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 12/20 0.77
RET P07949 4/20 0.58
MAPK14 Q16539 4/20 0.58
ABL1 P00519 3/20 0.58
EPHA2 P29317 3/20 0.58
MAP3K20 Q9NYL2 3/20 0.58
PLK4 O00444 2/20 0.58
AURKA O14965 2/20 0.58
MAPK13 O15264 2/20 0.58
MAP4K4 O95819 2/20 0.58
LCK P06239 2/20 0.58
FYN P06241 2/20 0.58
LYN P07948 2/20 0.58
SRC P12931 2/20 0.58
RPS6KB1 P23443 2/20 0.58
AXL P30530 2/20 0.58
FRK P42685 2/20 0.58
MAPK9 P45984 2/20 0.58
BLK P51451 2/20 0.58
CAMK2B Q13554 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4548729 0.91 KDR (0.64) KDRRETMAPK14ABL1EPHA2
SCHEMBL2749251 0.89 KDR (0.70) KDRRAF1BRAFFGFR1CSF1R
SCHEMBL4548728 0.88 KDR (0.70) KDRRETMAPK14ABL1EPHA2
SCHEMBL2747600 0.87 KDR (1.00) KDRAURKALCKAURKBRAF1
SCHEMBL16620832 0.86 RAF1 (0.74) KDRRETMAPK14ABL1EPHA2
SCHEMBL4548761 0.85 KDR (0.66) KDRRAF1BRAFDDR2
SCHEMBL2747890 0.85 BRAF (0.59) KDRRETMAPK14ABL1EPHA2
SCHEMBL4548756 0.84 KDR (0.64) KDRRETMAPK14ABL1EPHA2
SCHEMBL2748022 0.84 KDR (0.64) KDRRAF1BRAFFGFR1MEN1
SCHEMBL19888727 0.83 RAF1 (0.75) KDRRETMAPK14ABL1EPHA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-8178557-B2 Compounds and methods of use AMGEN INC. (US) 2012-05-15 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-20090176774-A1 Compounds and methods of use AMGEN INC. (US) 2009-07-09 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-7435823-B2 Compounds and methods of use AMGEN INC. (US) 2008-10-14 US disclosed
US-20060241115-A1 Compounds and methods of use AMGEN INC. 2006-10-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241115-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885RET 138/4885MAPK14 1944/4885
US-20090176774-A1 Compounds and methods of use HGF, HGFAC, MET KDR 354/4885RET 138/4885MAPK14 1944/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.